Amylin Hit Hardest By Bydureon Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
Amylin Pharmaceuticals, Eli Lilly, and Alkermes, will all feel the financial effects of the diabetes drug's delay to different degrees.
You may also be interested in...
Bydureon Goes Back To The QTc Drawing Board
Amylin considers options for new study assessing cardiac safety, estimates resubmission timeline by year-end 2011.
Bydureon Goes Back To The QTc Drawing Board
Amylin considers options for new study assessing cardiac safety, estimates resubmission timeline by year-end 2011.
Alkermes Unveils Bydureon Royalties And Its Own Long-acting Form Of Lilly's Zyprexa
Risperdal Consta will be cash cow for years to come, but other drugs in pipeline will fill out revenue stream.